Team Sophie Bear
While she does still have some "active” tumor spots in various parts of the brain (unfortunately her tumor spread to other parts - most brain tumors do not) the big tumor is pretty much inactive on the MRI. From a scientific point of view this is considered a success because of 1) shrinkage in primary large tumor; and 2) stability in smaller tumor "spots.”
The drug is of course not without side effects, both known (for example, nausea) and unknown (how this agent will change her cell development in the long term). The next question is what to expect when Sophie gets off the drug - will the tumor stay small, or once the agent is not in her system, will it grow again. This is the issue to address when the clinical trial is over, at month 24 (October 2014).
Because the drug is not FDA-approved, Sophie cannot restart the drug once she is off it. The remaining options are traditional intravenous chemotherapy (which is not as effective and very hard on the body) or possibly a different school and routine.
Sophie's family is tremendously thankful for the opportunity to be a part of this clinical trial, while at the same time understanding the risks involved. We are all hopeful that there will be more pediatric-specific brain tumor trials in the future, and thank you for contributing to this very important cause.
|Denotes a Team Captain|